Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’
January 6th 2022An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
Read More
Pre-Surgical Keytruda Provides Promising Advancement in TNBC Treatment
December 20th 2021Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
Read More
Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL
December 14th 2021The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.
Read More
Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset
December 11th 2021Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.
Read More
Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma
December 10th 2021In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.
Watch
Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer
December 10th 2021The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.
Read More